U.K.-based Proteome Sciences has completed the in vivo phase of its CK1D inhibitor program in Alzheimer's disease. According to the company, both of its in-house compounds improve cognitive function in animals. The next step, which will start in January, will be to look at biomarkers and drug levels. Developing drugs to treat Alzheimer's disease has proved to be a complex process, and Proteome Sciences is basing its work on targeting tau tangles in the brain. Press release